Peter Smith
Director/Board Member at RYVU THERAPEUTICS S.A.
Peter Smith active positions
| Companies | Position | Start | End |
|---|---|---|---|
| RYVU THERAPEUTICS S.A. | Director/Board Member | 2023-06-13 | - |
Remix Therapeutics, Inc.
 Remix Therapeutics, Inc. BiotechnologyHealth Technology Remix Therapeutics, Inc. operates as a biotechnology company. It involves in developing small molecule therapies which are designed to reprogram RNA processing to address the underlying drivers of disease. The company was founded by Pete Smith and is headquartered in Cambridge, MA. | Chief Executive Officer | 2021-08-16 | - |
| Founder | - | - | |
| President | - | - | |
| Chief Tech/Sci/R&D Officer | - | 2021-08-16 | |
Atlas Venture Advisors, Inc.
 Atlas Venture Advisors, Inc. Investment ManagersFinance Atlas Venture Advisors Inc (Atlas Venture Advisors) is a venture capital firm founded in 1980 by Christopher Julian Spray. The firm is headquartered in Cambridge, Massachusetts. | Consultant / Advisor | 2017-12-31 | - |
Amplify Medicines, Inc.
 Amplify Medicines, Inc. Pharmaceuticals: GenericHealth Technology Part of Ikena Oncology, Inc., Amplify Medicines, Inc. develops pharmaceutical drugs. The company is based in Boston, MA. The company was founded by Peter Smith. | Chief Tech/Sci/R&D Officer | - | - |
| Founder | - | - |
Career history of Peter Smith
Former positions of Peter Smith
| Companies | Position | Start | End |
|---|---|---|---|
H3 Biomedicine, Inc.
 H3 Biomedicine, Inc. Pharmaceuticals: MajorHealth Technology Part of Eisai Co., Ltd., H3 Biomedicine, Inc. is a precision oncology research and development subsidiary based in Cambridge, MA. The company is uniquely positioned to integrate real-world clinical evidence with the latest advances in cancer genomics. H3 is developing a pipeline of highly targeted, breakthrough medicines that have the potential to impact the future of cancer care and treatment. The CEO of the company is Takashi Owa. | Corporate Officer/Principal | 2010-12-31 | 2018-12-30 |
Training of Peter Smith
| Newcastle University | Doctorate Degree |
| University of Sheffield Medical School | Undergraduate Degree |
Statistics
International
| United States | 5 |
| United Kingdom | 3 |
| Poland | 2 |
Operational
| Chief Tech/Sci/R&D Officer | 2 |
| Founder | 2 |
| Chief Executive Officer | 1 |
Sectoral
| Health Technology | 5 |
| Consumer Services | 3 |
| Finance | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 1 |
|---|---|
| RYVU THERAPEUTICS S.A. | Health Technology |
| Private companies | 4 |
|---|---|
Remix Therapeutics, Inc.
Remix Therapeutics, Inc. BiotechnologyHealth Technology Remix Therapeutics, Inc. operates as a biotechnology company. It involves in developing small molecule therapies which are designed to reprogram RNA processing to address the underlying drivers of disease. The company was founded by Pete Smith and is headquartered in Cambridge, MA. | Health Technology |
Atlas Venture Advisors, Inc.
Atlas Venture Advisors, Inc. Investment ManagersFinance Atlas Venture Advisors Inc (Atlas Venture Advisors) is a venture capital firm founded in 1980 by Christopher Julian Spray. The firm is headquartered in Cambridge, Massachusetts. | Finance |
Amplify Medicines, Inc.
Amplify Medicines, Inc. Pharmaceuticals: GenericHealth Technology Part of Ikena Oncology, Inc., Amplify Medicines, Inc. develops pharmaceutical drugs. The company is based in Boston, MA. The company was founded by Peter Smith. | Health Technology |
H3 Biomedicine, Inc.
H3 Biomedicine, Inc. Pharmaceuticals: MajorHealth Technology Part of Eisai Co., Ltd., H3 Biomedicine, Inc. is a precision oncology research and development subsidiary based in Cambridge, MA. The company is uniquely positioned to integrate real-world clinical evidence with the latest advances in cancer genomics. H3 is developing a pipeline of highly targeted, breakthrough medicines that have the potential to impact the future of cancer care and treatment. The CEO of the company is Takashi Owa. | Health Technology |
- Stock Market
- Insiders
- Peter Smith
- Experience
